- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
News 165 results
Recognition
September 28, 2022
LMG Life Sciences Recognizes King & Spalding With Multiple Rankings in its 2022 Guide
In the News · Source: Biosimilars Review & Report
September 22, 2022
Eva Temkin discusses the effects of the Inflation Reduction Act and explains why by 2029, there could be 60 drugs on the target listed
In the News · Source: Law360 and Bloomberg Law
September 12, 2022
Keri Borders and Dale Giali represent Kind before a New York federal court, which dismissed a consumer deception class action suit against the company
In the News · Source: Politico
September 8, 2022
Preeya Pinto is named an adjunct professor of law at the Catholic University of America
In the News · Source: Pink Sheet
September 6, 2022
Eva Temkin explains why biosimilar applicants likely have not tried to obtain labeling claims relating to switching with other biosimilars
In the News · Source: Law360
In the News · Source: 340B Report
August 25, 2022
John Shakow discusses the U.S. Health Resources and Services Administration pausing the publication of limited distribution plan notices
In the News · Source: Law360, Bloomberg Law, Reuters and Cook County Record
August 16, 2022
Marisa Maleck and Anne Voigts counsel Walmart before the Seventh Circuit
In the News · Source: Law Street Media
July 27, 2022
K&S counsels Melinta Therapeutics in a patent dispute with the FDA, HHS and its Secretary Xavier Becerra
In the News · Source: Law360
Press Release
June 28, 2022
King & Spalding Broadens FDA and Life Sciences Team with Addition of Three Partners